^
    Back
    Association details:
    Biomarker:HER-2 negative
    Cancer:HER2 Negative Breast Cancer
    Drug:carboplatin (Tubulin polymerization promoter) +
    docetaxel (Tubulin polymerization promoter, Microtubule stabilizer)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Title:

    NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Breast Cancer

    Published date:
    01/25/2024
    Excerpt:
    Preoperative/adjuvant therapy regimens, HER2- Negative Regimens...Other Recommended Regimens...Docetaxel + carboplatin (4–6 cycles)
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Triple Negative Breast Cancer Trial

    Excerpt:
    ......
    Trial ID:
    NCT00532727
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer

    Excerpt:
    ...- Her-2 negative (IHC 0, 1+ without FISH, or IHC 2+ with...
    Trial ID:
    NCT05475678
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Neoadjuvant Carboplatin and Docetaxel in Triple Negative Breast Cancer

    Excerpt:
    ...- Breast cancer must be ER-negative, and HER-2 negative according to CAP/ASCO biomarkers testing guidelines....
    Trial ID:
    CADENCE
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    New
    Source:
    clinicaltrials.gov
    Title:

    Neoadjuvant Treatment of Triple Negative Breast Cancer Patients With Docetaxel and Carboplatin to Assess Anti-tumor Activity

    Excerpt:
    ...- HER2 negative by FISH or IHC staining 0 or 1+....
    Trial ID:
    NCT02124902